Abstract
The demonstration of tumor-associated cell-surface antigens, and specific immune responses to these antigens, in both animal and human tumors, has led to immunotherapeutic approaches to the control of a number of neoplasms [12]. Following the demonstration that bacillus Calmette-Guérin (BCG) vaccine is a potent non-specific immunostimulant in a variety of animal tumor models [17], clinical trials were conducted in leukemia [11] and melanoma [1]. The initial clinical results were encouraging, but they have been empirical and arbitrary in regard to dose, route, schedule, and type (strain) of BCG preparation used.
Supported by: U.S. Public Health Service Contract PH 43 68 949 from the Collaborative Research Program, Transplantation-Immunology Branch, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, and Grants CA 05831 and FR 05511 from the National Institutes of Health.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bluming, A. Z., Vogel, C. L., Ziegler, J. L., Mod; N., Kamya, G • Immunological effects of BCG in malignant melanoma: Two modes of administration compared. Ann. intern. Med. 76, 405 (1972).
Curtis, J. E., Hersh, E. M., Harris, J. E., Mcbride, C. E., Freireich, E. J.: Immune response to keyhole limpet haemocyanin: Inter-relationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin. exp. Immunol. 6, 473 (1970).
Eilber, F. R., Morton, D. L.: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer (Philad) 25, 362 (1969).
Faguet, G. B., Balcerzak, S. P., LoBuGLIO, A. F.: A new phytohemagglutinin (PHA) assay for detecting defective cellular immunity in neoplasia. (Abstract No. 113). American Society of Hematology 66, (1971).
Gatti, R. A., Harrioch, D. B., Goon, R. A.: Depressed PHA responses in patients with non-lymphoid malignancies. In: Proceedings of the Fifth Leukocyte Culture Conference (HARRIS, J. E., Ed.), p. 339. New York: Academic Press 1970.
Hersh, E. M., Curtis, J. E., Harris, J. E., Mcbride, C., Alexanian, R., Rossen, R.: Host defense mechanisms in lymphoma and leukemia. In: Leukemia-Lymphoma, p. 146. 1970.
Hersh, E. M.: Blastogenic responses of human lymphocytes to Xenogeneic cells in vitro. Transplantation 12, 287 (1971).
Jones, I. H., Hardisty, R. M., Wells, D. G., Kay, H. E. M.: Lymphocyte transformation in patients with acute lymphoblastic leukemia. Brit. med. J. 1971 IV, 329.
Lee, A. K. Y., Rowley, M., Mackay, I. R.: Antibody-producing capacity in human cancer. Brit. J. Cancer 24, 454 (1970).
Mathe, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. R., Hayat, M., DE Vassal, F.: Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969 II, 697.
Maths, G., Pouillart, P., Lapeyraque, F.: Active immunotherapy of L 1210 leukemia applied after the graft of tumor cells. Brit. J. Cancer 23, 814 (1969).
Maths, G.: Active immunotherapy. Advances Cancer Res. 14, 1 (1971).
Mathé, G., Amiel, J. L., Schwarzeneerg, L.: Preliminary result of a new protocol for the active immunotherapy of acute lymphoblastic leukemia: Inhibition of the immunotherapeutic effect by vincristine or adamatadine. Rev. Europ. Etud. clin. biol. 16, 216 (1971).
Mcbride, C. M.: Advanced melanoma of the extremities. Arch. Surg. 101, 122 (1970).
Morton, D. L.: Immunological studies with human neoplasms. J. reticuloenthoth. Soc. 10, 137 (1971).
Nathanson, L., Hall, T. C., Vawter, G. F., Farber, S.: Melanoma as a medical problem. Arch. intern. Med. 119, 479 (1967).
Old, L. J., Benacerraf, B., Clarke, D. A., Carswell, E. A., Stockerte: The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 21, 1281 (1961).
Preliminary report of working part on Leukemia in Childhood: Treatment of acute lymphoblastic leukemia. Comparison of Immunotherapy (BCG), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen (Concord Trial). Brit. med. J. 1971 IV 189.
Reif, A. E., Kim, C. A. H.: Leukemia L 1210 therapy trials with antileukemia serum and bacillus Calmette Guerin. Cancer Res. 31, 1606 (1971).
Stehlin, J. S., Hills, W. J., Rufino, C.: Disseminated melanoma. Arch. Surg. 94, 495 (1967).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1974 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Gutterman, J.U., Mavligit, G., McBride, C.M., Frei, E., Hersh, E.M. (1974). BCG Stimulation of Immune Responsiveness in Patients with Malignant Melanoma. In: Mathé, G., Weiner, R. (eds) Investigation and Stimulation of Immunity in Cancer Patients. Recent Results in Cancer Research, vol 47. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-49284-6_71
Download citation
DOI: https://doi.org/10.1007/978-3-642-49284-6_71
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-49286-0
Online ISBN: 978-3-642-49284-6
eBook Packages: Springer Book Archive